Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Impacto de la suplementación con micronutrientes antes del embarazo en los resultados maternos e infantiles

30 de septiembre de 2026 actualizado por: Usha Ramakrishnan, Emory University

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Low birth weight and anemia remain intractable problems in many developing countries despite considerable efforts to address them. Intervening with just prenatal iron-folate (IFA) supplements may not be the best approach given the substantial demands for iron by maternal and fetal tissues. Therefore, there is an urgent need to evaluate the additional contribution of prepregnancy interventions.

Low birth weight (LBW) and anemia remain public health problems in many developing countries. There is a great deal of evidence in the literature that anemia, primarily due to iron deficiency, has been associated with poor birth outcomes and LBW. The most common interventions is the provision of iron-folate (IFA) supplements during pregnancy. Despite several decades of effort, the success of these interventions in improving anemia and LBW was limited due to: inadequate coverage, high costs and an inability to sustain the programs. Reasons for low effectiveness also include inadequacy of delivery systems, side effects and poor compliance among pregnant women. In addition, intervening with iron-folate (IFA) supplements during pregnancy alone may not be sufficient as many women enter pregnancy with suboptimal iron stores. Weekly pre-pregnancy IFA supplementation (WIFS) has been introduced as a way to reduce the burden of anemia and improve birth outcomes. WIFS has been shown to improve iron status and reduce the burden of anemia in Women of Reproductive Age (WRA) in the short term, but no study has assessed the effects of this intervention on birth outcomes.

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status. The study will be conducted in Vietnam, a developing country, where anemia and Iron Deficiency (ID) are highly prevalent and will provide valuable scientific evidence that will inform policy. Infants born to women receiving the intervention are followed up to age 10 to 11 to assess periconception nutrition on early adolescent body size, anemic status, cognitive and academic achievement.

Tipo de estudio

Intervencionista

Inscripción (Actual)

5011

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Thái Nguyên
      • Thai Nguyen, Thái Nguyên, Vietnam, 24000
        • Thai Nguyen University of Medicine and Pharmacy

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 35 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria for Women:

  • 18-35 years old
  • Currently married
  • Currently living in one of the 10 communes and intends to live in the areas for 24 months following recruitment
  • Plans to have children in the next year
  • Agrees to participate with informed consent

Exclusion Criteria for Women:

  • Currently pregnant
  • Delivered in the previous six months
  • Regularly consumed IFA or MM supplements in the past 2 months
  • Severe anemia (Hb < 7 g/L)
  • History of high risk pregnancy including abruptio placenta, placenta previa, gestational diabetes, pregnancy induced hypertension, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use
  • Chronic hematological diseases, hereditary defects of red cells or hemoglobin

Inclusion Criteria for Offspring:

  • Child of a female participant of the original study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Multiple Micronutrient - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Comparador activo: Iron and Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current World Health Organization (WHO) recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Comparador de placebos: Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

Experimental: Multiple Micronutrient - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Comparador activo: Iron and Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Comparador de placebos: Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Birth Size - Weight
Periodo de tiempo: At birth

Infant weight is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Weight is measured in grams (g).

At birth
Birth Size - Body Length
Periodo de tiempo: At birth

Infant length is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Length is measured in millimeters (mm).

At birth
Birth Size - Head Circumference
Periodo de tiempo: At birth

Infant head circumference is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Head circumference is measured in millimeters (mm).

At birth
Gestational Age
Periodo de tiempo: At birth

Gestational age is calculated based on the date of last menstrual period. This method has been shown to be reliable in previous work and the researchers expect precise estimates since women will be visited weekly from baseline during the pre-pregnancy period. Women who have delivered babies in the past 6 months are excluded.

At birth
Child length
Periodo de tiempo: From Birth to 24 months

Child length, measured in millimeters (mm) is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From Birth to 24 months
Child weight
Periodo de tiempo: From birth through 24 months of age

Child weight, measured in grams (g), is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From birth through 24 months of age
Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III) Score
Periodo de tiempo: 12 and 24 months

Child development is measured using the Bayley Scales of Infant and Toddler Development - Third Edition at 12 and 24 months of age. The Bayley-III is a standardized comprehensive assessment tool for assessing child development in children one month to 42 months old. The highest possible scaled score on each subtest is 19, and the lowest possible score is 1. Scores from 8 to 12 are considered average. Index scores for motor and language domains are derived from sums of the subtest scaled scores. Index scores range from 40-160 with higher scores indicating. Composite scores are calculated for the cognitive, language, and motor scales to compare children to a normative age-matched sample. Composite scores have a mean of 100 with a standard deviation of 15. Composite scores below 85 indicate mild cognitive impairment and scores below 70 indicate moderate to severe cognitive impairment.

12 and 24 months
Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Score
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age

Child development is measured using the WISC-IV. This test has been validated and adapted in the Vietnamese context and takes 60-70 minutes to administer. The WISC-IV consists of 10 subtests (Vocabulary, Similarities, Comprehension, Block Design, Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and Symbol search). These are summed into four indices: the Verbal Comprehension Index (VCI, a measure of crystallized abilities), Perceptual Reasoning Index (PRI, a measure of inductive and quantitative reasoning), Working Memory Index (WMI, a measure of children's ability to memorize new information), Processing Speed Index (PSI, a measure of the speed of information processing including the ability to focus attention and quickly scan, discriminate and sequentially order visual information). The Full-Scale intelligence quotient (IQ) score ranges from 40 to 160 points with higher scores indicating higher intelligence. Scores of 90 to 109 are considered average.

6 to 7 years of age, 10 to 11 years of age
Weight-for-age Z score (WAZ)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age

The weight-for-age Z score (WAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Height-for-Age Z Score (HAZ)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age

The height-for-age Z score (HAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Weight-for-Height Z Score (WHZ)
Periodo de tiempo: 6 to 7 years of age

The weight-for-height Z score (WHZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age
Body Mass Index Z Score (BMI-Z)
Periodo de tiempo: 10 to 11 years of age

The body mass index Z Score (BMI-Z) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

10 to 11 years of age
Body composition (Lean mass/fat free mass index)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age

Body composition (Lean mass/fat free mass index) in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements

6 to 7 years of age, 10 to 11 years of age

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mothers' iron status
Periodo de tiempo: At baseline, 1 month postpartum, 3 months postpartum

Venous blood samples (5 ml) will be collected from women at: baseline, the first prenatal visit and at 1 and 3 months post partum. Anemia will be defined as Hb value <12 g/L for non-pregnant women, and <11g/L for pregnant women and infants, and iron deficiency as serum ferritin <12 μg/L (93).

At baseline, 1 month postpartum, 3 months postpartum
Infants' iron status
Periodo de tiempo: Birth, 3 months of age

Infant iron status is measured in cord blood samples (5 ml) obtained at delivery and at 3 months of age using a capillary blood sample that is obtained from a heel prick. The hemoglobin concentration are measured from a drop of blood using the HEMOCUE B- Hb photometer. The blood samples are then centrifuged and serum samples are aliquoted into microcuvettes and handled in the same way as described for mothers. Serum ferritin and transferrin receptor concentrations will be assayed using the ELISA method.

Birth, 3 months of age
Center for Epidemiological Studies Depression Scale (CES-D) Score
Periodo de tiempo: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report instrument asking respondents if they have experienced symptoms of depression during the past week. Responses are given on a scale of 0 to 3 where rarely is scored as 0 and most of the time is scored as 3. Total scores range from 0 to 60 and higher scores indicate greater symptoms of depression.

At baseline, during pregnancy, 3 months postpartum
Edinburgh Postnatal Depression Scale (EPDS) Score
Periodo de tiempo: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Edinburgh Postnatal Depression Scale (EPDS). The EPDS includes 10-items asking participants about symptoms of depression that they have experienced in the past 7 days. Responses are given on a 4-point scale where 0 corresponds with the least amount of symptoms and 3 corresponds with the highest amount of symptoms. Total scores range from 0 to 30 with higher scores indicating increased symptoms of depression. Scores of 10 and greater indicate possible depression.

At baseline, during pregnancy, 3 months postpartum

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Academic Achievement
Periodo de tiempo: 10 to 11 years of age

Academic achievement is evaluated with an assessment tool that has been used previously in Vietnam as part of the Young Lives Study. Study participants will take assessments in mathematics and Vietnamese (reading) at the beginning of the academic year when they enter Grade 5 in the school setting. Each test will take approximately 45 minutes. The test instruments in both math and reading employ a 30-item multiple-choice format and were developed in consultation with curriculum experts from the Vietnamese National Institute of Educational Sciences and are in line with those employed in the Ministry of Education & Training (MOET)/World Bank Grade 5 Study to measure learning levels in relation to curricular expectations, covering key subject domains at a range of levels of cognitive demand.

10 to 11 years of age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Usha Ramakrishnan, PhD, Emory University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de octubre de 2011

Finalización primaria (Actual)

1 de septiembre de 2014

Finalización del estudio (Actual)

1 de agosto de 2023

Fechas de registro del estudio

Enviado por primera vez

13 de agosto de 2012

Primero enviado que cumplió con los criterios de control de calidad

14 de agosto de 2012

Publicado por primera vez (Estimado)

15 de agosto de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB00051384
  • 10-1196-UEMORY-01 (Otro identificador: Other)
  • 2025P009844 (Otro identificador: Emory IRB)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .